Trial of Ketamine and Lithium Therapy in Bipolar Depression

NCT01768767 | Withdrawn Phase 2

• 2 other identifiers: 1209010758T32DA022975
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is looking at the safety and efficacy of combined ketamine and lithium therapy for treating patients with bipolar depression who are taking a mood stabilizer that is not working for them.

Conditions

Bipolar Depression

Outcome Measures

Primary Outcomes (1)

• Montgomery-Asberg Depression Rating Scale (MADRS)

  4 Hours to 2 weeks

Secondary Outcomes (2)

• Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR)

  4 hours to 2 weeks

• Clinical Global Impressions Scale (CGI)

  4 hours to 2 weeks

Other Outcomes (3)

• Young Mania Rating Scale (YMRS)

  4 hours to 2 weeks

• Brief Psychotic Rating Scale (BPRS)

  1 and 4 hours

• Clinician-Administered Dissociative States Scale (CADSS)

  1 and 4 hours

Study Arms (3)

Ketamine/Lithium

EXPERIMENTAL

Participant will receive ketamine/lithium

Drug: Ketamine/Lithium

Ketamine

ACTIVE COMPARATOR

Participant will receive ketamine

Drug: Ketamine

Placebo

PLACEBO COMPARATOR

Participant will receive placebo

Drug: Placebo

Interventions

Placebo DRUG

Placebo

Ketamine DRUG

Ketamine

Ketamine/Lithium DRUG

Ketamine/Lithium

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female between the ages of 18-65 years. Females will be included if they are not pregnant and agreed to utilize a medically accepted birth control method (to include oral, injectable, or implant birth control, condom, diaphragm with spermicide, intrauterine device, tubal ligation, abstinence, or partner with vasectomy) or if post-menopausal for at least 1 year, or surgically sterile.
• Able to provide written informed consent according to Yale HIC guidelines.
• Bipolar Disorder in Major Depressive Episode (296.5x or 296.89), as determined by the Structured Clinical Interview for DSM-IV (SCID) patient edition 80
• Montgomery Asberg Depression Rating Scale (MADRS) score of 18 or higher.
• Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR16) score of 19 or higher.
• Be able to understand and speak English.

You may not qualify if:

• Patients with a history of DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder or currently exhibiting psychotic features associated with their depression.
• Patients with current hypomanic and/or manic symptoms meeting DSM-IV-TR criteria of mixed episode are excluded.
• DSM IV-TR Axis I disorders are excluded if they are considered primary disorders.
• Serious suicide or homicide risk, as assessed by evaluating clinician; A serious suicide risk will be considered an inability to control suicide attempts, imminent risk of suicide in the investigator's judgment, or a history of serious suicidal behavior, which is defined using the Columbia-Suicide Severity Rating Scale (C-SSRS) as either (1) one or more actual suicide attempts in the 3 years before study entry with the lethality rated at 3 or higher, or (2) one or more interrupted suicide attempts with a potential lethality judged to result in serious injury or death.
• Substance abuse or dependence during the 3 months prior to screening.
• History of serious medical or neurological illness.
• Signs of major medical or neurological illness on examination or as a result of a 12 lead ECG screening or laboratory studies.
• Abnormality on physical examination. A subject with a clinical abnormality may be included only if the study physician considers the abnormality will not introduce additional risk factors and will not interfere with the study procedure.
• Positive urine drug screen.
• Pregnant or lactating women or a positive urine pregnancy test; for women of childbearing potential.
• Subjects who test positive for HIV or viral hepatitis (hepatitis B and/or C) will be excluded as a means to (1) protect the subjects and research staff from the increased risks of blood borne pathogen transmission during placebo/ketamine infusions and (2) to minimize the factors which might influence the biochemical responses and affect the study outcome. This test will take place at the screening visit. Subjects will be invited back to the Yale Depression Research Program, either for their next study visit or for a HIV/Hep debriefing session. HIV results will be given in a face to face meeting no matter what the results are.
• Patients requiring excluded medications (see Table 3 for details).
• History indicating learning disability or mental retardation.
• Known sensitivity to ketamine or lithium.
• Resting blood pressure lower than 90/60 or higher than 150/90,or resting heart rate lower than 50/min or higher than 100/min.

Sponsors & Collaborators

• Yale University: lead
• National Institute on Drug Abuse (NIDA): collaborator

MeSH Terms

Conditions

Bipolar Disorder

Interventions

Ketamine; Lithium

Condition Hierarchy (Ancestors)

Bipolar and Related Disorders; Mood Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Metals, Alkali; Elements; Inorganic Chemicals; Metals, Light; Metals

Study Officials

• Chadi Abdallah, MD

  Yale University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 9, 2013
• First Posted: January 15, 2013
• Study Start: January 1, 2013
• Primary Completion: January 1, 2013
• Study Completion: January 1, 2013
• Last Updated: March 1, 2023

Record last verified: 2020-03